TANDEM DIABETES CARE INC - 8-K Filing
Tandem Diabetes Care reported Q1 2026 financial results with $247.2 million in worldwide sales, up 5% YoY, driven by 29,000 pump shipments and a 55% gross margin (up 480 bps YoY). The company reaffirmed full-year guidance of $1.065–$1.085 billion in sales, 56–57% gross margin, and 5–6% adjusted EBITDA margin. Strategic updates included a pay-as-you-go reimbursement model in the U.S. pharmacy channel and Android compatibility for its Tandem Mobi ecosystem. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TNDM